ORIGINAL PAPER
Reduced regulatory B cell subsets in mild to moderate hypertriglyceridemia: a preliminary study
1
Unidad de Investigación Biomédica, Delegación Zacatecas, Instituto Mexicano del Seguro Social, IMSS, México
2
División Académica Multidisciplinaria de Jalpa de Méndez, Universidad Juárez Autónoma de Tabasco, Jalpa de Méndez, Tabasco, México
3
Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Manuel Nava 6, Zona Universitaria, 78210, San Luis Potosí, SLP, México
4
Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, Sierra Leona 550, Lomas de San Luis, 78210, San Luis Potosí, SLP, México
Submission date: 2025-05-30
Final revision date: 2025-10-01
Acceptance date: 2025-10-09
Online publication date: 2026-09-24
Corresponding author
Mariana H. Garcia-Hernandez
1Unidad de Investigación Biomédica, Delegación Zacatecas, Instituto Mexicano del Seguro Social, IMSS, México
1Unidad de Investigación Biomédica, Delegación Zacatecas, Instituto Mexicano del Seguro Social, IMSS, México
KEYWORDS
ABSTRACT
Introduction:
This study evaluated the percentages of peripheral regulatory B cell subsets (CD19+CD24+CD38+, CD19+CD24+CD27+ and CD19+IL-10+) in patients with hypertriglyceridemia (HTG). In addition, interleukin (IL)-6, IL-10, and IL-1Ra levels were assessed. Finally, the impact of the saturated fatty acid palmitate on IL-10 production by B cells from HTG patients was examined.
Material and Methods:
The percentages of B cells were determined by flow cytometry. The levels of IL-6, IL-1Ra, and IL-10 were measured using ELISA assays.
Results:
The percentages of CD19+CD24+CD38+ and CD19+CD24+CD27+ cells were significantly lower in patients with moderate HTG compared to individuals with a normal lipid (NL) profile. The percentage of CD19+IL-10+ cells was lower in both HTG and moderate HTG patients compared to the NL group. The percentage of CD19+CD24+CD27+ cells was inversely associated with triglyceride (TG) levels and total cholesterol (TC). IL-10 production by B cells in the presence of palmitate was reduced in patients with moderate HTG compared to the NL group. Production of IL-6 by PBMC from HTG patients increased, while IL-10 production decreased; however, these changes did not reach statistical significance. HTG patients showed elevated serum levels of IL-1Ra compared to the NL group, and IL-1Ra levels were positively correlated with TG levels.
Conclusions:
Patients with moderate HTG exhibit alterations in regulatory B cell phenotypes. A reduction in the percentage of CD19+CD24+CD27+ regulatory B cells is associated with elevated TG levels.
This study evaluated the percentages of peripheral regulatory B cell subsets (CD19+CD24+CD38+, CD19+CD24+CD27+ and CD19+IL-10+) in patients with hypertriglyceridemia (HTG). In addition, interleukin (IL)-6, IL-10, and IL-1Ra levels were assessed. Finally, the impact of the saturated fatty acid palmitate on IL-10 production by B cells from HTG patients was examined.
Material and Methods:
The percentages of B cells were determined by flow cytometry. The levels of IL-6, IL-1Ra, and IL-10 were measured using ELISA assays.
Results:
The percentages of CD19+CD24+CD38+ and CD19+CD24+CD27+ cells were significantly lower in patients with moderate HTG compared to individuals with a normal lipid (NL) profile. The percentage of CD19+IL-10+ cells was lower in both HTG and moderate HTG patients compared to the NL group. The percentage of CD19+CD24+CD27+ cells was inversely associated with triglyceride (TG) levels and total cholesterol (TC). IL-10 production by B cells in the presence of palmitate was reduced in patients with moderate HTG compared to the NL group. Production of IL-6 by PBMC from HTG patients increased, while IL-10 production decreased; however, these changes did not reach statistical significance. HTG patients showed elevated serum levels of IL-1Ra compared to the NL group, and IL-1Ra levels were positively correlated with TG levels.
Conclusions:
Patients with moderate HTG exhibit alterations in regulatory B cell phenotypes. A reduction in the percentage of CD19+CD24+CD27+ regulatory B cells is associated with elevated TG levels.
REFERENCES (47)
1.
Chait A, Feingold KR (2023): Approach to patients with hypertriglyceridemia. Best Pract Res Clin Endocrinol Metab 37: 101659.
2.
Christian JB, Arondekar B, Buysman EK, et al. (2014): Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia. Am J Med 127: 36-44.e1.
3.
Miller M (1998): Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart J 19 Suppl H: H18.
4.
Zhang T, Hou Y, Liu M, et al. (2023): Correlation between the levels of ANGPTL3, ANGPTL4, ANGPTL8 and postprandial triglyceride-rich lipoprotein (TRL). Diabetes Metab Syndr Obes 16: 3979-3993.
5.
Esser D, van Dijk SJ, Oosterink E, et al. (2013): A high-fat SFA, MUFA, or n3 PUFA challenge affects the vascular response and initiates an activated state of cellular adherence in lean and obese middle-aged men. J Nutr 143: 843-851.
6.
Huang ZS, Chien KL, Yang CY, et al. (2001): Peripheral differential leukocyte counts in humans vary with hyperlipidemia, smoking, and body mass index. Lipids 36: 237-245.
7.
Devaraj S, Wang-Polagruto J, Polagruto J, et al. (2008): High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome. Metabolism 57: 867-870.
8.
Gao Q, Jiang Y, Ma T, et al. (2010): A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 185: 5820-5827.
9.
Smith E, Prasad KM, Butcher M, et al. (2010): Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 121: 1746-1755.
10.
Hong N, Lin Y, Ye Z, et al. (2022): The relationship between dyslipidemia and inflammation among adults in east coast China: A cross-sectional study. Front Immunol 13: 937201.
11.
Somm E, Cettour-Rose P, Asensio C, et al. (2006): Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 49: 387-393.
12.
Juge-Aubry CE, Somm E, Giusti V, et al. (2003): Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 52: 1104-1110.
13.
Nishimura S, Manabe I, Takaki S, et al. (2013): Adipose natural regulatory B cells negatively control adipose tissue inflammation. Cell Metab 18: 759-766.
14.
de Almeida IT, Cortez-Pinto H, Fidalgo G, et al. (2002): Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr 21: 219-223.
15.
Wen H, Gris D, Lei Y, et al. (2011): Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12: 408-415.
16.
Prieur X, Mok CY, Velagapudi VR, et al. (2011): Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. Diabetes 60: 797-809.
17.
Haversen L, Danielsson KN, Fogelstrand L, Wiklund O (2009): Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis 202: 382-393.
18.
Slusher AL, Mischo AB, Acevedo EO (2016): Pentraxin 3 is an anti-inflammatory protein associated with lipid-induced interleukin 10 in vitro. Cytokine 86: 36-40.
19.
Rosser EC, Mauri C (2015): Regulatory B cells: origin, phenotype, and function. Immunity 42: 607-612.
20.
van der Vlugt LE, Zinsou JF, Ozir-Fazalalikhan A, et al. (2014): Interleukin 10 (IL-10)-producing CD1dhi regulatory B cells from Schistosoma haematobium-infected individuals induce IL-10-positive T cells and suppress effector T-cell cytokines. J Infect Dis 210: 1207-1216.
21.
Iwata Y, Matsushita T, Horikawa M, et al. (2011): Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117: 530-541.
22.
Flores-Borja F, Bosma A, Ng D, et al. (2013): CD19+-CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 5: 173ra23.
23.
Wei B, Deng Y, Huang Y, et al. (2019): IL-10-producing B cells attenuate cardiac inflammation by regulating Th1 and Th17 cells in acute viral myocarditis induced by coxsackie virus B3. Life Sci 235: 116838.
24.
Mauri C, Gray D, Mushtaq N, Londei M (2003): Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197: 489-501.
25.
Kyaw T, Tay C, Krishnamurthi S, et al. (2011): B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res 109: 830-840.
26.
Strom AC, Cross AJ, Cole JE, et al. (2015): B regulatory cells are increased in hypercholesterolaemic mice and protect from lesion development via IL-10. Thromb Haemost 114: 835-847.
27.
Zhang Y, Jiang Y, Zou Y, et al. (2023): Peripheral blood CD19 positive B lymphocytes increase after ischemic stroke and correlate with carotid atherosclerosis. Front Neurol 14: 1308041.
28.
Fischer E, Van Zee KJ, Marano MA, et al. (1992): Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79: 2196-2200.
29.
Granowitz EV, Santos AA, Poutsiaka DD, et al. (1991): Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 338: 1423-1424.
30.
Wang H, Zhang S, Xie L, et al. (2023): Neuroinflammation and peripheral immunity: Focus on ischemic stroke. Int Immunopharmacol 120: 110332.
31.
Westendorp WF, Dames C, Nederkoorn PJ, Meisel A (2022): Immunodepression, infections, and functional outcome in ischemic stroke. Stroke 53: 1438-1448.
32.
Murakami Y, Saito H, Shimizu S, et al. (2019): Increased regulatory B cells are involved in immune evasion in patients with gastric cancer. Sci Rep 9: 13083.
33.
Potteaux S, Esposito B, van Oostrom O, et al. (2004): Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 24: 1474-1478.
34.
Rincon-Arevalo H, Quintero JC, Fortich F, et al. (2020): Low frequency of IL-10(+) B cells in patients with atherosclerosis is related with inflammatory condition. Heliyon 6: e03441.
35.
Shen P, Roch T, Lampropoulou V, et al. (2014): IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507: 366-370.
36.
Ferramosca A, Zara V (2014): Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol 20: 1746-1755.
37.
Mendez-Frausto G, Romero-Aguilera G, Sanchez-Gutierrez R, et al. (2021): B regulatory cells associated with changes in biochemical and inflammatory parameters in normal-glycemic individuals, pre-diabetes and T2DM patients. Diabetes Res Clin Pract 173: 108692.
38.
Blair PA, Norena LY, Flores-Borja F, et al. (2010): CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32: 129-140.
39.
Menon M, Blair PA, Isenberg DA, Mauri C (2016): A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity 44: 683-697.
40.
Hayashi M, Yanaba K, Umezawa Y, et al. (2016): IL-10-producing regulatory B cells are decreased in patients with psoriasis. J Dermatol Sci 81: 93-100.
41.
Banko Z, Pozsgay J, Szili D, et al. (2017): Induction and differentiation of IL-10-producing regulatory B cells from healthy blood donors and rheumatoid arthritis patients. J Immunol 198: 1512-1520.
42.
Wilson HL, Francis SE, Dower SK, Crossman DC (2004): Secretion of intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation. J Immunol 173: 1202-1208.
43.
Hannum CH, Wilcox CJ, Arend WP, et al. (1990): Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336.
44.
Feingold KR, Soued M, Adi S, et al. (1991): Effect of interleukin-1 on lipid metabolism in the rat. Similarities to and differences from tumor necrosis factor. Arterioscler Thromb 11: 495-500.
45.
Klemettila JP, Kampman O, Seppala N, et al. (2014): Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry Res 218: 277-283.
46.
Luotola K (2022): IL-1 receptor antagonist (IL-1Ra) levels and management of metabolic disorders. Nutrients 14: 3422.
47.
Majcher S, Ustianowski P, Tarnowski M, et al. (2021): IL-1beta and IL-10 gene polymorphisms in women with gestational diabetes. J Matern Fetal Neonatal Med 34: 3169-3174.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
